

Supplements

Supplementary Table 1: Characteristics of study population separated by gender

characteristic	female HCWs	male HCWs
absolute number of subjects (share on the study population)	1,379 (81%)	325 (19%)
Age (IQR) [years]	39 (29-53)	37 (31-48)
BMI (IQR) [kg/m ²]	23·4 (21·1-26·7)	24·5 (22·6-27·1)
smoking [absolute number] (share among the gender group)	163 (11·8%)	48 (14·8%)
vaccine-related sick leave		
number of sick days after the first COVID-19 vaccination	114	10
number of sick days after the second COVID-19 vaccination	658	77
number of sick days after the third COVID-19 vaccination	623	68
number on HCWs on sick leave after first COVID-19 vaccination (share among the gender group)	59 (4·3%)	5 (1·5%)
number on HCWs on sick leave after second COVID-19 vaccination (share among the gender group)	331 (24%)	39 (12%)
number on HCWs on sick leave after third COVID-19 vaccination (share among the gender group)	338 (24·5%)	40 (12·3%)
post-vaccination PRN medication		
number of HCWs with post-vaccination PRN medication, first dose administration (share among the gender group)	331 (24·0%)	54 (16·6%)
number of HCWs with post-vaccination PRN medication, second dose administration (share among the gender group)	682 (49·6%)	102 (31·5%)
number of HCWs with post-vaccination PRN medication, third dose administration (share among the gender group)	964 (86·0%)	201 (85·9%)

Supplementary Table 1: Characterisation of the study population separated by gender; percentages indicate the respective share of the female and male sub-cohort. Age and BMI are reported as medians with interquartile ranges in brackets.